Our in vivo findings are the first to demonstrate that disruption of the CD47-SIRPα axis and/or Fc mediated tumor cell opsonization results in a more pro-inflammatory immune presence based on the higher M1 content within treated tumors. The gene discussed is SIRPA; the disease is neoplasm.